According to the 2019 EULAR recommendations, different drugs that target relevant immune system molecules are currently used for the management of RA: non-steroidal anti-inflammatory drugs, glucocorticoids, immunosuppressants and disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), leflunomide, sulfasalazine (SSZ) and hydroxycloroquine (HCQ), Janus kinase inhibitors (JAKi) (baricitinib, tofacitinib y upadacitinib) and biological DMARDs (TNF inhibitors (TNFi), abatacept (ABA), rituximab (RTX), tocilizumab (TCZ) and sarilumab) [4]. The gene discussed is TNF; the disease is rheumatoid arthritis.